Cencora (COR) Stock Price, Fundamentals & Analysis

What COR does

Cencora (COR) is a stock in the Healthcare sector, specifically in the Medical Distribution industry. The company sources and distributes pharmaceutical products in the United States and internationally. Its U.S. Healthcare Solutions segment supplies generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to hospitals, retail pharmacies, mail order pharmacies, medical clinics, long-term care facilities, and other customers. It also distributes plasma, blood products, vaccines, and specialty pharmaceuticals, while providing pharmacy management, staffing, consulting, supply management software, packaging solutions, clinical trial support, and data analytics services to healthcare providers and biotechnology and pharmaceutical manufacturers. In addition, the company supplies pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients to the companion animal and production animal markets, along with sales force services to manufacturers.

Key numbers explained

• 312.28 USD is the latest price for one share of Cencora on the US market.
• The trailing P/E ratio of 23.2 shows how much investors pay per dollar of the company's last 12 months of earnings; a lower figure can suggest a stock is cheaper relative to current earnings.
• The forward P/E ratio of 15.8 uses expected future earnings, which can make the stock look more attractive if those earnings grow.
• 13.46 USD is the earnings per share over the trailing 12 months, representing the portion of profit allocated to each outstanding share.
• The dividend yield of 0.76% tells you the annual cash payout relative to the share price; it is modest compared with high-yield stocks.
• The ex-dividend date of Aug 14, 2026 is the cutoff to own the stock and receive the next dividend payment.
• 17% of earnings are paid out as dividends, meaning the company retains most of its profit for reinvestment or other uses.
• Beta of 0.57 indicates the stock has historically moved less than the overall market, which can mean lower volatility.
• The 52-week price range of 244.82 – 377.54 shows the lowest and highest traded prices in the past year, while the current price sits below the midpoint.
• Market cap of 59.59B USD places Cencora among large-cap companies, and it is part of the S&P 500.
• Revenue of 332.77 mld. USD with 5.1% year-over-year growth reflects the scale and pace of top-line expansion.
• Profit margin of 0.8% and operating margin of 1.4% highlight how thin earnings are relative to sales, a common feature in capital-intensive distribution businesses.
• Return on equity of 96.9% shows how efficiently the company generates profit from shareholders' equity, though it can be influenced by high leverage.
• The debt-to-equity ratio of 446.5% signals that the company carries a substantial amount of debt compared with equity, which is typical for large distributors.
• Price-to-book of 19.53 compares the market price to the accounting value of equity, often elevated for companies with strong intangibles or expected growth.
• Next earnings date is Nov 4, 2026, the scheduled release of the company's latest financial results.

Recent news

Recent headlines focus on Cencora's specialty growth strategy and managed services organization expansion, including its ties with Walgreens. One piece questions whether the stock is still below fair value after a raised EPS outlook and a 1B buyback. Another asks what the catch is in the raised guidance and the large repurchase program.

What to watch

Investors in Cencora often monitor healthcare policy and drug pricing regulations, which can affect distribution volumes and margins. The company's ability to grow specialty pharmacy services and manage large customer relationships, such as those with major health systems and payers, is another key factor. Because it operates in the same space as peers like McKesson Corporation (MCK), DaVita (DVA), and HCA Healthcare (HCA), broader industry trends in medical distribution and hospital services can influence its performance.